{"title":"Intranasal delivery of leuprolide acetate chitosan nanoparticles for treatment of Alzheimer’s disease","authors":"A. Dharamsi, T. Pandya","doi":"10.2174/2210303113666230120124831","DOIUrl":null,"url":null,"abstract":"\n\nPresent research work aims to develop Chitosan nanoparticles of leuprolide acetate for intranasal delivery in the treatment of Alzheimer’s disease.\n\n\n\nAlzheimer’s disease (AD) is one of the leading causes and the most prevalent form of age-related dementia worldwide. There is an urgent surge to find an effective treatment for AD due to the social implications it poses on society.\n\n\n\nTo formulate Leuprolide acetate chitosan nanoparticles for intranasal delivery\n\n\n\nChitosan nanoparticles encapsulating leuprolide acetate were prepared using the ionic gelation method and optimized using a central composite design. The optimized nanoparticles were evaluated by DSC study, TEM analysis, in vitro and ex vivo drug release study, histopathology study, and accelerated stability study, In vivo kinetic and dynamic study.\n\n\n\nThe optimized formulation exhibited particle size of 254.3 ± 10.7 nm, \n\n\n\nThus, the chitosan nanoparticulate formulation of leuprolide acetate was found to have great potential for Alzheimer’s disease management.\n\n\n\nNA\n","PeriodicalId":11310,"journal":{"name":"Drug Delivery Letters","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery Letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2210303113666230120124831","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Present research work aims to develop Chitosan nanoparticles of leuprolide acetate for intranasal delivery in the treatment of Alzheimer’s disease.
Alzheimer’s disease (AD) is one of the leading causes and the most prevalent form of age-related dementia worldwide. There is an urgent surge to find an effective treatment for AD due to the social implications it poses on society.
To formulate Leuprolide acetate chitosan nanoparticles for intranasal delivery
Chitosan nanoparticles encapsulating leuprolide acetate were prepared using the ionic gelation method and optimized using a central composite design. The optimized nanoparticles were evaluated by DSC study, TEM analysis, in vitro and ex vivo drug release study, histopathology study, and accelerated stability study, In vivo kinetic and dynamic study.
The optimized formulation exhibited particle size of 254.3 ± 10.7 nm,
Thus, the chitosan nanoparticulate formulation of leuprolide acetate was found to have great potential for Alzheimer’s disease management.
NA
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
